Peter Joyce - founding a virtual biotech
The Bioinformatics CRO Podcast
00:00
The Impact of COVID on Graywolf Therapeutics
E-RAP1 and E-RAP2 inhibitors have shown promising results in some cancer types. But there are still a lot of patients who aren't seeing prolonged benefit beyond one to two years, says Graywolf's CEO. The company runs as if it were a project team inside a larger organization so that all the different parties working together on novel drugs can deliver them into the clinic.
Play episode from 02:25
Transcript
